Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 12;7:11253. doi: 10.1038/s41598-017-10542-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

mRNA expression of associated genes in responders and non-responders before and after ADI-PEG20 treatment. (A) The relative mRNA expression levels of RHAG, ANK1, and NPM1 in the bone marrow mononuclear cells (BMMCs) of Case 1 and Case 2 at the indicated time points by QR-PCR. BMMC1B is the BMMCs of Case 1 before ADI-PEG20 treatment. BMMC1A is the BMMCs of Case 1 after ADI-PEG20 and in complete remission status. BMMC1R is the BMMCs of Case 1 collected at the time of relapse after ADI-PEG20 treatment. BMMC2B is the BMMCs of Case 2 before ADI-PEG20 treatment. BMMC2A is the BMMCs of Case 2 after ADI-PEG20 and in complete remission. The samples of BMMC1B and BMMC1R were compared with BMMC1A for analysis. The sample of BMMC2B was compared with BMMC1A for analysis. (B) The mRNA expression of c-MYC in AML cases responsive and non-responsive to ADI-PEG20. (left) Fold changes of mRNA expression of c-MYC in BMMC1B, and 1 R relative to BMMC1A and in BMMC 2B relative to BMMC2A. Case 1 and Case 2 were responders to ADI-PEG20. (right) Fold changes of mRNA expression of c-MYC in BMMC4A, 9 A, 10 A, 11 A, and 14 A relative to BMMC4B, 9B, 10B, 11B, and 14B, respectively. Cases 4, 9, 10, 11, and 14 were non-responders to ADI-PEG20. (Cases 4, 10, and 11were PD; Cases 9 and 14 were SD) “A” indicates after ADI-PEG20, “B” indicates before ADI-PEG20.